Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (vascular endothelial cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: uproleselan, rivipansel, bimosiamose +1 | 0.90 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 1 Parkinson's papers of 396 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 3769
Sealed predictions
- SELE in dopamine neurons, braak-0.03 (p 0.946) → -0.06 (p 0.874)receipt 3778
Swarm cases
receipt 3778: SELE in dopamine neurons, braak
- power
- full sample +0.01 (p 0.962, n 18), 95% CI -0.46 to +0.48. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.01 (p 0.962, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.11 (p 0.658, n 18). could be the mix.
- skeptic
- leave-one-out range -0.08 to +0.15, sign flips 10; without severely affected donors +0.01 (p 0.962, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SELE in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts